DRDermot F. Reilly

Dermot F. Reilly

*This is an algorithmically generated author record based on publicly available information.

Dermot F. Reilly has a total of 623 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Vascular Endothelial Growth Factor Receptor 1–Blocking Antibody Improves Endothelial Structure, Kidney Function, and GFR in Diabetic Mice

    by Jingjun Li, Romer A. Gonzalez Villalobos, Thomas J. Rutkoski, Krista P. Farrington, Vaja Chipashvili, Gang Zheng, Tao Chen, Krishna Yekkala, Monica Locatelli, Carlamaria Zoja, et al.

    Key Points: We found evidence for reduced vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 activation in both human and mouse diabetic kidney disease. A monoclonal vascular endothelial growth factor receptor 1–blocking antibody improved urine albumin-creatinine ratio and GFR in a mouse model of accelerated diabetic kidney disease. The mechanism for this benefit appears to be linked to increased endogenous vascular endothelial growth factor A and differentiates from lisinopril. Background: Diabetic kidney disease (DKD) remains the major cause of kidney failure. Vascular endothelial growth factor A (VEGFA)-neutralizing antibodies also cause kidney disease in normal people. The present studies explored whether endogenous VEGFA deficiency might contribute to DKD. Methods: Plasma soluble vascular endothelial growth factor receptor 1 (VEGFR1; aka sflt1), the VEGFR1 ligands VEGFA, and placental growth factor were measured in human DKD plasma samples from the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial. We also tested the effects of monoclonal antibody designation for murinized anti-mouse VEGFR1 receptor (VGFB1), a murinized VEGFR1-blocking antibody in the uninephrectomy renin expressing adeno-associated virus db/db DKD mouse including translational end points of serum creatinine and overall survival. Histology, transmission electron microscopy, and RNA sequencing of mouse kidneys treated with or without VGFB1 or lisinopril were compared. Results: Circulating soluble Flt1 and placental growth factor were higher in CREDENCE participants with lower eGFR, while intrarenal VEGFA mRNA decreased with lower eGFR. VEGFR1 blockade with the VGFB1 mAb improved overall sinistrin clearance, serum creatinine, albuminuria, BP, and kidney structure in uninephrectomy renin expressing adeno-associated virus db/db mice. VGFB1 treatment benefit differentiated from lisinopril by increasing endothelial fenestrae and glycocalyx-related genes. Compared with lisinopril, VGFB1 also significantly increased glomerular endothelial genes including Emcn, Esm1, Ehd3, and Exoc3l2. Conclusions: An anti-VEGFR1 antibody restored VEGFA activity, endothelial health, and GFR in severe murine DKD. This effect was via a mechanism distinct from lisinopril.


  • Top Cited Papers
    Open Access

    Leveraging complementary multi-omics data integration methods for mechanistic insights in kidney diseases

    by Fadhl Alakwaa, Vivek Das, Arindam Majumdar, Viji Nair, Damian Fermin, Asim B. Dey, Timothy Slidel, Dermot F. Reilly, Eugene Myshkin, Kevin L. Duffin, et al.

    Chronic kidney diseases (CKDs) are a global health concern, necessitating a comprehensive understanding of their complex pathophysiology. This study explores the use of 2 complementary multidimensional -omics data integration methods to elucidate mechanisms of CKD progression as a proof of concept. Baseline biosamples from 37 participants with CKD in the Clinical Phenotyping and Resource Biobank Core (C-PROBE) cohort with prospective longitudinal outcome data ascertained over 5 years were used to generate molecular profiles. Tissue transcriptomic, urine and plasma proteomic, and targeted urine metabolomic profiling were integrated using 2 orthogonal multi-omics data integration approaches, one unsupervised and the other supervised. Both integration methods identified 8 urinary proteins significantly associated with long-term outcomes, which were replicated in an adjusted survival model using 94 samples from an independent validation group in the same cohort. The 2 methods also identified 3 shared enriched pathways: the complement and coagulation cascades, cytokine–cytokine receptor interaction pathway, and the JAK/STAT signaling pathway. Use of different multiscalar data integration strategies on the same data enabled identification and prioritization of disease mechanisms associated with CKD progression. Approaches like this will be invaluable with the expansion of high-dimension data in kidney diseases.


  • Open Access

    X-chromosome and kidney function: evidence from a multi-trait genetic analysis of 908,697 individuals reveals sex-specific and sex-differential findings in genes regulated by androgen response elements

    by Markus Scholz, Katrin Horn, Janne Pott, Matthias Wuttke, Andreas Kühnapfel, M Kamal Nasr, Holger Kirsten, Yong Li, Anselm Hoppmann, Mathias Gorski, et al.

    X-chromosomal genetic variants are understudied but can yield valuable insights into sexually dimorphic human traits and diseases. We performed a sex-stratified cross-ancestry X-chromosome-wide association meta-analysis of seven kidney-related traits (n = 908,697), identifying 23 loci genome-wide significantly associated with two of the traits: 7 for uric acid and 16 for estimated glomerular filtration rate (eGFR), including four novel eGFR loci containing the functionally plausible prioritized genes ACSL4, CLDN2, TSPAN6 and the female-specific DRP2. Further, we identified five novel sex-interactions, comprising male-specific effects at FAM9B and AR/EDA2R, and three sex-differential findings with larger genetic effect sizes in males at DCAF12L1 and MST4 and larger effect sizes in females at HPRT1. All prioritized genes in loci showing significant sex-interactions were located next to androgen response elements (ARE). Five ARE genes showed sex-differential expressions. This study contributes new insights into sex-dimorphisms of kidney traits along with new prioritized gene targets for further molecular research.


  • Open Access

    The genetic background shapes the susceptibility to mitochondrial dysfunction and NASH progression

    by Giorgia Benegiamo, Giacomo V.G. von Alvensleben, Sandra Rodríguez-López, Ludger J.E. Goeminne, Alexis M. Bachmann, Jean-David Morel, Ellen Broeckx, Jing Ying Ma, Vinicius Carreira, Sameh A. Youssef, et al.

    Non-alcoholic steatohepatitis (NASH) is a global health concern without treatment. The challenge in finding effective therapies is due to the lack of good mouse models and the complexity of the disease, characterized by gene–environment interactions. We tested the susceptibility of seven mouse strains to develop NASH. The severity of the clinical phenotypes observed varied widely across strains. PWK/PhJ mice were the most prone to develop hepatic inflammation and the only strain to progress to NASH with extensive fibrosis, while CAST/EiJ mice were completely resistant. Levels of mitochondrial transcripts and proteins as well as mitochondrial function were robustly reduced specifically in the liver of PWK/PhJ mice, suggesting a central role of mitochondrial dysfunction in NASH progression. Importantly, the NASH gene expression profile of PWK/PhJ mice had the highest overlap with the human NASH signature. Our study exposes the limitations of using a single mouse genetic background in metabolic studies and describes a novel NASH mouse model with features of the human NASH.


  • The Use of Genomics to Drive Kidney Disease Drug Discovery and Development

    by Dermot F. Reilly, Matthew D. Breyer

    As opposed to diseases such as cancer, autoimmune disease, and diabetes, identifying drugs to treat CKD has proven significantly more challenging. Over the past 2 decades, new potential therapeutic targets have been identified as genetically altered proteins involved in rare monogenetic kidney diseases. Other possible target genes have been implicated through common genetic polymorphisms associated with CKD in the general population. Significant challenges remain before translating these genetic insights into clinical therapies for CKD. This paper will discuss how genetic variants may be leveraged to develop drugs and will especially focus on those genes associated with CKD to exemplify the value and challenges in including genetic information in the drug development pipeline.


  • Open Access

    FAM13A affects body fat distribution and adipocyte function

    by Mohsen Fathzadeh, Jiehan Li, Abhiram Rao, Naomi Cook, Indumathi Chennamsetty, Marcus Seldin, Xiang Zhou, Panjamaporn Sangwung, Michael J. Gloudemans, Mark Keller, et al.

    Genetic variation in the FAM13A (Family with Sequence Similarity 13 Member A) locus has been associated with several glycemic and metabolic traits in genome-wide association studies (GWAS). Here, we demonstrate that in humans, FAM13A alleles are associated with increased FAM13A expression in subcutaneous adipose tissue (SAT) and an insulin resistance-related phenotype (e.g. higher waist-to-hip ratio and fasting insulin levels, but lower body fat). In human adipocyte models, knockdown of FAM13A in preadipocytes accelerates adipocyte differentiation. In mice, Fam13a knockout (KO) have a lower visceral to subcutaneous fat (VAT/SAT) ratio after high-fat diet challenge, in comparison to their wild-type counterparts. Subcutaneous adipocytes in KO mice show a size distribution shift toward an increased number of smaller adipocytes, along with an improved adipogenic potential. Our results indicate that GWAS-associated variants within the FAM13A locus alter adipose FAM13A expression, which in turn, regulates adipocyte differentiation and contribute to changes in body fat distribution.


  • Protein-coding variants implicate novel genes related to lipid homeostasis contributing to body-fat distribution

    by Anne E. Justice, Tugce Karaderi, Heather M. Highland, Kristin L. Young, Mariaelisa Graff, Yingchang Lu, Valérie Turcot, Paul L. Auer, Rebecca S. Fine, Xiuqing Guo, et al.

    Body-fat distribution is a risk factor for adverse cardiovascular health consequences. We analyzed the association of body-fat distribution, assessed by waist-to-hip ratio adjusted for body mass index, with 228,985 predicted coding and splice site variants available on exome arrays in up to 344,369 individuals from five major ancestries (discovery) and 132,177 European-ancestry individuals (validation). We identified 15 common (minor allele frequency, MAF ≥5%) and nine low-frequency or rare (MAF Drosophila RNAi-knockdowns, we observed a significant increase in the total body triglyceride levels for two genes (DNAH10 and PLXND1). We implicate novel genes in fat distribution, stressing the importance of interrogating low-frequency and protein-coding variants.


  • Open Access

    Interethnic analyses of blood pressure loci in populations of East Asian and European descent

    by Fumihiko Takeuchi, Masato Akiyama, Nana Matoba, Tomohiro Katsuya, Masahiro Nakatochi, Yasuharu Tabara, Akira Narita, Woei-Yuh Saw, Sanghoon Moon, Cassandra N. Spracklen, et al.

    Blood pressure (BP) is a major risk factor for cardiovascular disease and more than 200 genetic loci associated with BP are known. Here, we perform a multi-stage genome-wide association study for BP (max N = 289,038) principally in East Asians and meta-analysis in East Asians and Europeans. We report 19 new genetic loci and ancestry-specific BP variants, conforming to a common ancestry-specific variant association model. At 10 unique loci, distinct non-rare ancestry-specific variants colocalize within the same linkage disequilibrium block despite the significantly discordant effects for the proxy shared variants between the ethnic groups. The genome-wide transethnic correlation of causal-variant effect-sizes is 0.898 and 0.851 for systolic and diastolic BP, respectively. Some of the ancestry-specific association signals are also influenced by a selective sweep. Our results provide new evidence for the role of common ancestry-specific variants and natural selection in ethnic differences in complex traits such as BP.


  • Open Access

    Genetic invalidation of Lp-PLA2 as a therapeutic target: Large-scale study of five functional Lp-PLA2-lowering alleles

    by John M Gregson, Daniel F Freitag, Praveen Surendran, Nathan O Stitziel, Rajiv Chowdhury, Stephen Burgess, Stephen Kaptoge, Pei Gao, James R Staley, Peter Willeit, et al.

    Subscription and open access journals from SAGE Publishing, the world's leading independent academic publisher.